Related Experiment Video
Updated: Aug 29, 2025
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Teserpaturev/G47Δ: First Approval.
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. bdr@adis.com.
Teserpaturev/G47Δ (Delytact®) is a novel oncolytic virus therapy. It has gained approval in Japan for treating malignant glioma, marking a significant milestone in cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Oncology
Background:
- Teserpaturev/G47Δ (Delytact®) is a third-generation, triple-mutated recombinant oncolytic herpes simplex virus type 1.
- Developed by Daiichi Sankyo Co., Ltd. for treating solid cancers.
Purpose of the Study:
- To summarize the development milestones of teserpaturev/G47Δ.
- To highlight its first approval for malignant glioma treatment.
Main Methods:
- Review of development history and clinical trial data.
- Analysis of regulatory submission and approval process.
Main Results:
- Teserpaturev/G47Δ received approval for malignant glioma treatment in Japan.
- Ongoing clinical trials for prostate cancer, malignant pleural mesothelioma, and olfactory neuroblastoma.
Conclusions:
- Teserpaturev/G47Δ represents a significant advancement in oncolytic virotherapy.
- The approval signifies a new therapeutic option for malignant glioma patients.
More Related Videos
08:01Rapid Scan Electron Paramagnetic Resonance Opens New Avenues for Imaging Physiologically Important Parameters In Vivo
Published on: September 26, 2016
16:02Quantitative FRET Förster Resonance Energy Transfer Analysis for SENP1 Protease Kinetics Determination
Published on: February 21, 2013